Tyme Technologies (NSDQ:TYME) announced today that it received a U.S. patent for its metabolomic drug delivery platform.
Bedminster, N.J.-based Tyme’s additional patent claims related to the metabolomic technology platform (U.S. Patent No. 11,058,638) involves the targeted delivery of therapeutics to cancer cells.
The company’s technology fuses the tyrosine isomer racemetryosine (α-methylparatyrosine) with a second therapeutic agent that creates a compound that may allow the targeted delivery to cancer cells in a novel manner, according to a news release.
Such a delivery method is predicated on a metabolic process in which cancer cells consume higher quantities of non-essential amino acids from their surrounding environment, Tyme said. That consumption includes tyrosine and supports growth because the cells can’t make enough of the amino acids.
The investigational delivery technology is currently in the pre-clinical phase of development and not approved in the U.S. for any disease indication. It requires further studies, which Tyme plans to initiate later this year.
“This technology could provide Tyme an opportunity to expand its current cancer-metabolism based approach with a drug delivery platform that’s aimed to deliver toxic therapies in a targeted manner that could offer improved safety and efficacy for a range of anticancer drugs.” Tyme CSO Steve Hoffman said in the release.
“This delivery technology is another example of our innovative spirit at Tyme. Even though this approach is still in its early stages, if proven, it has the potential to be a broadly leveraged platform technology.” added Tyme CEO Richie Cunningham.
